Continue Reading
Full article on Bloomberg
Generic Ozempic Will Upend the Global Weight-Loss Drug Market
Market Intelligence Analysis
AI-Powered
Why This Matters
Novo Nordisk may face a 13% drop in sales in 2026 due to the expiration of its Ozempic patents, potentially allowing generic versions to compete in the weight-loss drug market.
Market Impact
Market impact analysis based on bearish sentiment with 90% confidence.
Sentiment
Bearish
AI Confidence
90%
Time Horizon
Short Term
Article Context
Note: This is a brief excerpt for context. Click below to read the full article on the original source.
Novo Nordisk is predicting a 13% drop in sales in 2026. As the company’s patents on Ozempic expire, could cheaper, generic versions give the company a run for its money? Big Take host David Gura talks to Bloomberg reporters Naomi Kresge and Amber Tong about what comes next. (Source: Bloomberg)
Original article published by
Bloomberg
on February 5, 2026.
Analysis and insights provided by AnalystMarkets AI.
Analysis and insights provided by AnalystMarkets AI.